Biomarkers for trials of neuroprotection in Parkinson's disease.
about
NMR Metabolomics Analysis of Parkinson's DiseasePathogenesis-targeted, disease-modifying therapies in Parkinson disease.Cerebrospinal fluid biomarker candidates for parkinsonian disorders.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Neuropathology of α-synuclein propagation and braak hypothesis.Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers.The vatican meeting on neuroprotection for Parkinson's disease.
P2860
Q35734379-4227A263-659C-4CFF-A4F5-CA241CF10E94Q37506492-0483E8EC-7F8A-4B44-B835-587AFAD5000DQ38076411-05E0487E-A36E-45C8-93D6-D645FF26DEA1Q38275171-08760845-A63C-4D40-9D2F-6F4F39DE8CE8Q38580816-673991C5-D4A3-4849-B1C9-285EFF18E2DAQ39067542-87D4FE46-BE23-4A9B-B03C-B5D88B06693DQ44513107-109A8936-A79F-4809-8629-0F5FA2DF9239
P2860
Biomarkers for trials of neuroprotection in Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biomarkers for trials of neuroprotection in Parkinson's disease.
@en
type
label
Biomarkers for trials of neuroprotection in Parkinson's disease.
@en
prefLabel
Biomarkers for trials of neuroprotection in Parkinson's disease.
@en
P2860
P356
P1433
P1476
Biomarkers for trials of neuroprotection in Parkinson's disease.
@en
P2093
A Jon Stoessl
Pankaj A Agarwal
P2860
P356
10.1002/MDS.25065
P407
P577
2012-08-24T00:00:00Z